Tatiana M Lopera-Mesa1, Saibou Doumbia2, Drissa Konaté2, Jennifer M Anderson1, Mory Doumbouya2, Abdoul S Keita2, Seidina A S Diakité2, Karim Traoré2, Michael A Krause1, Ababacar Diouf3, Samuel E Moretz3, Gregory S Tullo3, Kazutoyo Miura3, Wenjuan Gu4, Michael P Fay5, Steve M Taylor6, Carole A Long1, Mahamadou Diakité2, Rick M Fairhurst7. 1. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. 2. Malaria Research and Training Center, University of Bamako, Bamako, Mali. 3. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA; Kelly Scientific Resources, Rockville, MD, USA. 4. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 5. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. 6. Division of Infectious Diseases and International Health and Duke Global Health Institute, Duke University Medical Center, Durham, NC, USA; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 7. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. Electronic address: rfairhurst@niaid.nih.gov.
Abstract
BACKGROUND: Red blood cell variants protect African children from severe falciparum malaria. However, their individual and interactive effects on mild disease and parasite density, and their modification by age-dependent immunity, are poorly understood. In this study, we address these knowledge gaps in a prospective cohort study of malaria risk and Plasmodium falciparum densities in Malian children. METHODS: The Kenieroba Innate Defense Study for Malaria (KIDS-Malaria) was a 4-year prospective cohort study of children aged 6 months to 17 years undertaken in Mali between 2008 and 2011. Red blood cell variants were haemoglobin S (HbS), haemoglobin C (HbC), α thalassaemia, ABO blood groups, and glucose-6-phosphate dehydrogenase (G6PD) deficiency encoded by the X-linked A- allele. The primary outcome was malaria incidence, measured as the number of uncomplicated or severe malaria episodes over time. The secondary outcome was parasite density at the time of a malaria episode. We modelled incidence rate ratios with quasi-Poisson regression and we analysed parasite densities using generalised estimating equations. This study is registered with ClinicalTrials.gov, number NCT00669084. FINDINGS: Between May 1, 2008, and Dec 29, 2011, we enrolled 1586 children into the study. We successfully typed all five red blood cell variants for 1543 of these children, who therefore constituted the evaluable population and in whom we diagnosed 4091 malaria episodes over 2656 child-years of follow-up. In these 1543 children, red blood cell variants were common, and occurred at the following frequencies: sickle cell trait (HbAS) 220 (14%), HbC heterozygosity (HbAC) 103 (7%), α thalassaemia 438 (28%), type O blood group 621 (40%), and G6PD deficiency 72 (9%) in 767 boys and 158 (20%) in 776 girls. The overall incidence of malaria was 1.54 episodes per child-year of follow-up, ranging from 2.78 episodes per child-year at age 3 years to 0.40 episodes per child-year at age 17 years. The malaria incidence was lower in HbAS children than in HbAA children with normal haemoglobin (adjusted incidence rate ratio [aIRR] 0.66 [95% CI 0.59-0.75], p<0.0001) and lower in G6PD A-/A- homozygous girls than in G6PD A+/A+ girls (0.51 [0.29-0.90], p=0.020), but was higher in HbAC children than in HbAA children (1.15 [1.01-1.32], p=0.039). Parasite density was lower in HbAS children (median 10,550 parasites per μL [IQR 1350-26,250]) than in HbAA children (15,150 parasites per μL [4250-31,050]; p=0.0004). The HbAS-associated reductions in malaria risk and parasite density were greatest in early childhood. INTERPRETATION: The individual and interactive effects of HbAS, HbAC, and G6PD A-/A- genotypes on malaria risk and parasite density define clinical and cellular correlates of protection. Further identification of the molecular mechanisms of these protective effects might uncover new targets for intervention. FUNDING: Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
BACKGROUND: Red blood cell variants protect African children from severe falciparum malaria. However, their individual and interactive effects on mild disease and parasite density, and their modification by age-dependent immunity, are poorly understood. In this study, we address these knowledge gaps in a prospective cohort study of malaria risk and Plasmodium falciparum densities in Malian children. METHODS: The Kenieroba Innate Defense Study for Malaria (KIDS-Malaria) was a 4-year prospective cohort study of children aged 6 months to 17 years undertaken in Mali between 2008 and 2011. Red blood cell variants were haemoglobin S (HbS), haemoglobin C (HbC), α thalassaemia, ABO blood groups, and glucose-6-phosphate dehydrogenase (G6PD) deficiency encoded by the X-linked A- allele. The primary outcome was malaria incidence, measured as the number of uncomplicated or severe malaria episodes over time. The secondary outcome was parasite density at the time of a malaria episode. We modelled incidence rate ratios with quasi-Poisson regression and we analysed parasite densities using generalised estimating equations. This study is registered with ClinicalTrials.gov, number NCT00669084. FINDINGS: Between May 1, 2008, and Dec 29, 2011, we enrolled 1586 children into the study. We successfully typed all five red blood cell variants for 1543 of these children, who therefore constituted the evaluable population and in whom we diagnosed 4091 malaria episodes over 2656 child-years of follow-up. In these 1543 children, red blood cell variants were common, and occurred at the following frequencies: sickle cell trait (HbAS) 220 (14%), HbC heterozygosity (HbAC) 103 (7%), α thalassaemia 438 (28%), type O blood group 621 (40%), and G6PD deficiency 72 (9%) in 767 boys and 158 (20%) in 776 girls. The overall incidence of malaria was 1.54 episodes per child-year of follow-up, ranging from 2.78 episodes per child-year at age 3 years to 0.40 episodes per child-year at age 17 years. The malaria incidence was lower in HbAS children than in HbAA children with normal haemoglobin (adjusted incidence rate ratio [aIRR] 0.66 [95% CI 0.59-0.75], p<0.0001) and lower in G6PD A-/A- homozygous girls than in G6PD A+/A+ girls (0.51 [0.29-0.90], p=0.020), but was higher in HbAC children than in HbAA children (1.15 [1.01-1.32], p=0.039). Parasite density was lower in HbAS children (median 10,550 parasites per μL [IQR 1350-26,250]) than in HbAA children (15,150 parasites per μL [4250-31,050]; p=0.0004). The HbAS-associated reductions in malaria risk and parasite density were greatest in early childhood. INTERPRETATION: The individual and interactive effects of HbAS, HbAC, and G6PD A-/A- genotypes on malaria risk and parasite density define clinical and cellular correlates of protection. Further identification of the molecular mechanisms of these protective effects might uncover new targets for intervention. FUNDING: Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Authors: D Modiano; G Luoni; B S Sirima; J Simporé; F Verra; A Konaté; E Rastrelli; A Olivieri; C Calissano; G M Paganotti; L D'Urbano; I Sanou; A Sawadogo; G Modiano; M Coluzzi Journal: Nature Date: 2001-11-15 Impact factor: 49.962
Authors: Benno Kreuels; Christina Kreuzberg; Robin Kobbe; Matilda Ayim-Akonor; Peter Apiah-Thompson; Benedicta Thompson; Christa Ehmen; Samuel Adjei; Iris Langefeld; Ohene Adjei; Jürgen May Journal: Blood Date: 2010-03-15 Impact factor: 22.113
Authors: Ana Ferreira; Ivo Marguti; Ingo Bechmann; Viktória Jeney; Angelo Chora; Nuno R Palha; Sofia Rebelo; Annie Henri; Yves Beuzard; Miguel P Soares Journal: Cell Date: 2011-04-29 Impact factor: 41.582
Authors: Gregory LaMonte; Nisha Philip; Joseph Reardon; Joshua R Lacsina; William Majoros; Lesley Chapman; Courtney D Thornburg; Marilyn J Telen; Uwe Ohler; Christopher V Nicchitta; Timothy Haystead; Jen-Tsan Chi Journal: Cell Host Microbe Date: 2012-08-16 Impact factor: 21.023
Authors: Tamara D Clark; Bryan Greenhouse; Denise Njama-Meya; Bridget Nzarubara; Catherine Maiteki-Sebuguzi; Sarah G Staedke; Edmund Seto; Moses R Kamya; Philip J Rosenthal; Grant Dorsey Journal: J Infect Dis Date: 2008-08-01 Impact factor: 5.226
Authors: Andrew E Fry; Michael J Griffiths; Sarah Auburn; Mahamadou Diakite; Julian T Forton; Angela Green; Anna Richardson; Jonathan Wilson; Muminatou Jallow; Fatou Sisay-Joof; Margaret Pinder; Norbert Peshu; Thomas N Williams; Kevin Marsh; Malcolm E Molyneux; Terrie E Taylor; Kirk A Rockett; Dominic P Kwiatkowski Journal: Hum Mol Genet Date: 2007-11-13 Impact factor: 6.150
Authors: Mahamadou Diakite; Kazutoyo Miura; Ababacar Diouf; Drissa Konate; Abdoul S Keita; Saibou Doumbia; Seidina Diakite; Karim Traore; Mory Doumbouya; Jennifer M Anderson; Rick M Fairhurst; Carole A Long Journal: Am J Trop Med Hyg Date: 2016-06-13 Impact factor: 2.345
Authors: Isabel Rodriguez-Barraquer; Emmanuel Arinaitwe; Prasanna Jagannathan; Moses R Kamya; Phillip J Rosenthal; John Rek; Grant Dorsey; Joaniter Nankabirwa; Sarah G Staedke; Maxwell Kilama; Chris Drakeley; Isaac Ssewanyana; David L Smith; Bryan Greenhouse Journal: Elife Date: 2018-07-25 Impact factor: 8.140
Authors: Wendy Prudhomme O'Meara; Ryan Simmons; Paige Bullins; Betsy Freedman; Lucy Abel; Judith Mangeni; Steve M Taylor; Andrew A Obala Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Leyre Pernaute-Lau; Ayola Akim Adegnika; Yitian Zhou; Jeannot F Zinsou; Jose Pedro Gil; Sanjeev Krishna; Peter G Kremsner; Volker M Lauschke; Thirumalaisamy P Velavan Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191